


ABSTRACT OF THE DISCLOSURE

This invention provides compounds defined by Formula I

5



- or a pharmaceutically acceptable salt thereof,
wherein R¹, Q, Y, R², R³, R⁴, R⁵, and n are as defined in the specification. The
invention also provides pharmaceutical compositions comprising a compound of
10 Formula I, or a pharmaceutically acceptable salt thereof, as defined in the
specification, together with a pharmaceutically acceptable carrier, diluent, or
excipient. The invention also provides methods of inhibiting an MMP-13 enzyme
in an animal, comprising administering to the animal a compound of Formula I, or
a pharmaceutically acceptable salt thereof. The invention also provides methods
15 of treating a disease mediated by an MMP-13 enzyme in a patient, comprising
administering to the patient a compound of Formula I, or a pharmaceutically
acceptable salt thereof, either alone or in a pharmaceutical composition. The
invention also provides methods of treating diseases such as heart disease,
multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or
20 rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart
failure, age-related macular degeneration, chronic obstructive pulmonary disease,
asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a
patient, comprising administering to the patient a compound of Formula I, or a
pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical
25 composition. The invention also provides combinations, comprising a compound
of Formula I, or a pharmaceutically acceptable salt thereof, together with another
pharmaceutically active component as described in the specification.